Skip to main
IGC

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma Inc. is positioned positively within the market due to its innovative cannabinoid-based formulations targeting critical medical conditions, particularly Alzheimer’s disease. The company’s investigational drug assets, such as IGC-AD1, have shown substantial promise in preclinical studies, indicating potential effectiveness in addressing key Alzheimer's disease hallmarks. With an attractive current valuation reinforced by a revised net present value (NPV) analysis suggesting significant upside, combined with anticipated positive data as a catalyst for growth, IGC Pharma holds a favorable outlook in the biotech sector.

Bears say

IGC Pharma Inc. reported a net loss of $1.6 million, corresponding to an earnings per share (EPS) of $(0.02), which aligns with consensus estimates but raises concerns about recurring financial losses. The company's challenges include significant risks related to its investigational drug assets, particularly pertaining to the safety and efficacy of its products in clinical trials, as well as the ability to secure regulatory approvals. Additionally, persistent balance sheet and liquidity risks, compounded by the competitive landscape and fluctuating investor sentiment toward biotech stocks, contribute to a negative outlook for the company's financial stability and growth potential.

IGC has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 2 analysts, IGC has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.